The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

Diabetes, Obesity and Metabolism

Volumn 7, Issue 1, 2005, Pages 65-72

  Poirier, Bruno ^a   Bidouard, J P ^a   Cadrouvele, C ^a   Marniquet, X ^a   Staels, B ^b   O'Connor, S E ^a   Janiak, P ^a   Herbert, J M ^a  

^a SANOFI   (France)

^b INSERM   (France)

Author keywords

Adiponectin; Body weight; CB1 receptor antagonist; Food intake; Glucose; Insulin; Lipoproteins; Obesity; Rimonabant

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 12744260206     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00374.x     Document Type: Article

References (28)

1. Bray GA. Obesity: a time bomb to be defused. Lancet 1998; 352: 160-161
2. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643.
3. Abate N. Obesity as a risk factor for cardiovascular disease. Am J Med 1999; 107: 12S-13S.
4. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003; 92: 35-42.
5. Rinaldi-Carmona M, Barth F, Heaulme M et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
6. Simiand J, Keane M, Keane PE, Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998; 9: 179-181.
7. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: L113-L117.
8. Di Marzo V, Goparaju SK, Wang L et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
9. Ravinet Trillou C, Arnone M, Delgorge C et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
10. Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
11. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311-1314.
12. Van Heek M, Compton DS, France CF et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385-390.
13. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167: 103-111.
14. Maffei M, Halaas J, Ravussin E et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
15. Sindelka G, Skrha J, Prazny M, Haas T. Association of obesity, diabetes, serum lipids and blood pressure regulates insulin action. Physiol Res 2002; 51: 85-91.
16. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30-36.
17. Melanson KJ, McInnis KJ, Rippe JM, Blackburn G, Wilson PF. Obesity and cardiovascular disease risk: research update. Cardiol Rev 2001; 9: 202-207.
18. Cota D, Marsicano G, Tschop M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
19. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
20. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-1881.
21. Fruebis J, Tsao TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010.
22. Masaki T, Chiba S, Yasuda T et al. Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in Agouti yellow (Ay/a) obese mice. Diabetes 2003; 52: 2266-2273.
23. Roberts CK, Vaziri ND, Liang KH, Barnard RJ. Reversibility of chronic experimental syndrome X by diet modification. Hypertension 2001; 37: 1323-1328.
24. Berger JJ, Barnard RJ. Effect of diet on fat cell size and hormone-sensitive lipase activity. J Appl Physiol 1999; 87: 227-232.
25. Roberts CK, Barnard RJ, Liang KH, Vaziri ND. Effect of diet on adipose tissue and skeletal muscle VLDL receptor and LPL: implications for obesity and hyperlipidemia. Atherosclerosis 2002; 161: 133-141.
26. Yamamoto Y, Hirose H, Saito I et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Colch) 2002; 103: 137-142.
27. Zietz B, Herfarth H, Paul G et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: 103-104.
28. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.